The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
In a recent study of the technology, a total of 90% of patients treated with the WaveWriter technology for three months reported at least a 50% improvement in their pain levels without an increased ...
Boston Scientific just won FDA approval for the first spinal cord neurostimulator system to provide both paresthesia-based and sub-perception therapy at the same time. The WaveWriter system delivers ...
MARLBOROUGH, Mass., Jan. 14, 2021 /PRNewswire/ -- Boston Scientific (NYSE: BSX) has announced a limited market release of the WaveWriter Alpha™ portfolio of Spinal Cord Stimulator (SCS) systems. The ...
Boston Scientific Corp. notched another win with the U.S. FDA approval of its spinal cord stimulator (SCS), Wavewriter, for treatment of non-surgical back pain just a week after receiving the agency’s ...
The FDA approved Boston Scientific's Spectra WaveWriter Spinal Cord Stimulator System. Here's what you should know: 1. The system is the first and only FDA-approved system that simultaneously provides ...
System offers multiple non-drug therapies for people with chronic pain PARIS, Jan. 31, 2019 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the launch of the Spectra ...
Boston Scientific, Inc. BSX recently received FDA approval for an expanded indication of the WaveWriter Alpha Spinal Cord Stimulator (“SCS”) Systems. With this approval, the system will be available ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results